Nymox (NYMXF) reports federal court grants motion to dismiss, case closed

Rhea-AI Filing Summary

Nymox Pharmaceutical Corporation filed a 6-K stating that the U.S. District Court for the Central District of California granted the Company’s and Computershare Investor Services Inc.’s motion to dismiss Christopher Riley’s complaint and dismissed the case, with prejudice.

A dismissal “with prejudice” means the case is closed and cannot be refiled on the same claims. This removes an outstanding legal matter for Nymox without indicating any financial terms. The report was signed on November 7, 2025.

Insights

Securities litigation analyst

Litigation dismissed with prejudice; legal overhang removed.

The federal court in the Central District of California granted dismissal of the Riley complaint against Nymox and Computershare, and did so with prejudice. That phrasing indicates finality regarding these claims, which typically reduces legal uncertainty.

The notice does not cite damages, settlements, or costs, so the financial effect is not quantified in this excerpt. The main takeaway is closure of a case that could have consumed management time and resources.

Subsequent filings may provide additional context on any related proceedings, if any exist, but this specific matter is concluded as stated.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of November, 2025

Commission File Number: 001-12033

Nymox Pharmaceutical Corporation

(Translation of registrant’s name into English)

Bay & Deveaux Streets, Nassau, The Bahamas

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

Nymox Pharmaceutical Corporation (the “Company”) reports that the U.S. District for the Central District of California granted the Company’s and Computershare Investor Services Inc.’s motion to dismiss Christopher Riley’s complaint, and dismissed the case, with prejudice.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 7, 2025

	NYMOX PHARMACEUTICAL CORPORATION
	By:	/s/ Paul Averback
	Name:	Paul Averback
	Title:	President and Chief Executive Officer

3

FAQ

What did Nymox (NYMXF) report in its latest 6-K?

The company reported that a U.S. federal court dismissed the Christopher Riley complaint against Nymox and Computershare, with prejudice.

Which court dismissed the case involving Nymox (NYMXF)?

The U.S. District Court for the Central District of California granted the dismissal.

Was the Nymox (NYMXF) case dismissed with prejudice?

Yes. The court dismissed the complaint with prejudice, closing the matter on those claims.

Who were the parties in the dismissed case related to Nymox (NYMXF)?

The dismissal covered a complaint by Christopher Riley against Nymox Pharmaceutical Corporation and Computershare Investor Services Inc.

When was the 6-K signed by Nymox (NYMXF)?

The report was signed on November 7, 2025 by the President and CEO.